Condition

Stage IB Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

Clinical trials12
Recruiting0
Common interventions23
Lead sponsors shown8

Clinical trials

12 shown
Icotinib for Completed Resected IB NSCLC With EGFR MutationNCT02264210 · 2015-01-01
COMPLETED
Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung CancerNCT02250378 · 2014-10-01
WITHDRAWN
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsNCT01999881 · 2013-12-01
COMPLETED
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor CareNCT01726296 · 2013-01-01
COMPLETED
Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung CancerNCT01741636 · 2013-01-01
COMPLETED
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerNCT01707823 · 2012-10-01
TERMINATED
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung CancerNCT01840150 · 2012-08-23
COMPLETED
Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant ChemotherapyNCT01595074 · 2012-05-01
NOT_YET_RECRUITING
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung CancerNCT01457469 · 2011-01-01
COMPLETED
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionNCT00087269 · 2004-12-01
TERMINATED
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryNCT00049543 · 2002-09-01
COMPLETED
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung CancerNCT00002852 · 1996-10-01
COMPLETED

Common interventions

Trial status mix

COMPLETED8
TERMINATED2
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

NA5
PHASE22
PHASE32
EARLY_PHASE11
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.